Relief Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
31
- Stock Symbol
-
RLF
- Investments
-
4
- Share Price
-
$3.88
- (As of Thursday Closing)
Relief Therapeutics General Information
Description
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
Contact Information
Website
www.relieftherapeutics.comCorporate Office
- Avenue de Sécheron 15
- 1202 Geneva
- Switzerland
Corporate Office
- Avenue de Sécheron 15
- 1202 Geneva
- Switzerland
Relief Therapeutics Timeline
Relief Therapeutics Stock Performance
As of 22-May-2025, Relief Therapeutics’s stock price is $3.88. Its current market cap is $48.6M with 12.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.88 | $2.58 | $1.23 - $8.63 | $48.6M | 12.5M | 32K | -$1.55 |
Relief Therapeutics Financials Summary
As of 31-Dec-2024, Relief Therapeutics has a trailing 12-month revenue of $9.6M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 49,187 | 49,187 | 18,200 | 114,396 |
| Revenue | 9,559 | 9,559 | 6,711 | 6,369 |
| EBITDA | (19,044) | (19,044) | (120,288) | (51,360) |
| Net Income | (19,442) | (19,442) | (109,221) | (53,193) |
| Total Assets | 58,907 | 58,907 | 90,947 | 203,635 |
| Total Debt | 2,372 | 2,372 | 3,519 | 3,305 |
Relief Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Relief Therapeutics Comparisons
Industry
Financing
Details
Relief Therapeutics Competitors (13)
One of Relief Therapeutics’s 13 competitors is Santhera Pharmaceuticals, a Private Debt Financed company based in Pratteln, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals | Private Debt Financed | Pratteln, Switzerland | ||||
| ObsEva | Formerly VC-backed | Geneva, Switzerland | ||||
| Genfit | Formerly VC-backed | Loos, France | ||||
| Idorsia Pharmaceuticals | Corporate Backed or Acquired | Allschwil, Switzerland | ||||
| Kala Bio | Formerly VC-backed | Arlington, MA |
Relief Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Relief Therapeutics Patents
Relief Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024127036-A | Isolation gown and manufacturing method thereof | Pending | 08-Mar-2023 |
Relief Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Relief Therapeutics Investments & Acquisitions (4)
Relief Therapeutics’s most recent deal was a Corporate Asset Purchase with NRx Pharmaceuticals (Zyesami). The deal was made on 20-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NRx Pharmaceuticals (Zyesami) | 20-Dec-2022 | Corporate Asset Purchase | Buildings and Property | ||
| AdVita Lifescience | 27-Jul-2021 | Merger/Acquisition | Pharmaceuticals | ||
| APR Applied Pharma Research | 28-Jun-2021 | Merger/Acquisition | Pharmaceuticals | ||
| THERAMetrics Holding | 14-Jul-2016 | Merger/Acquisition | Drug Discovery |
Relief Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 16, 2022
34.75 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Biotechnology
Subindustry
of 465
Rank
Percentile
Relief Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| APR Applied Pharma Research | Balerna, Switzerland | 1990 |
Relief Therapeutics FAQs
-
When was Relief Therapeutics founded?
Relief Therapeutics was founded in 2013.
-
Where is Relief Therapeutics headquartered?
Relief Therapeutics is headquartered in Geneva, Switzerland.
-
What is the size of Relief Therapeutics?
Relief Therapeutics has 31 total employees.
-
What industry is Relief Therapeutics in?
Relief Therapeutics’s primary industry is Biotechnology.
-
Is Relief Therapeutics a private or public company?
Relief Therapeutics is a Public company.
-
What is Relief Therapeutics’s stock symbol?
The ticker symbol for Relief Therapeutics is RLF.
-
What is the current stock price of Relief Therapeutics?
As of 22-May-2025 the stock price of Relief Therapeutics is $3.88.
-
What is the current market cap of Relief Therapeutics?
The current market capitalization of Relief Therapeutics is $48.6M.
-
What is Relief Therapeutics’s current revenue?
The trailing twelve month revenue for Relief Therapeutics is $9.6M.
-
Who are Relief Therapeutics’s competitors?
Santhera Pharmaceuticals, ObsEva, Genfit, Idorsia Pharmaceuticals, and Kala Bio are some of the 13 competitors of Relief Therapeutics.
-
What is Relief Therapeutics’s annual earnings per share (EPS)?
Relief Therapeutics’s EPS for 12 months was -$1.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
